

## Cemdisiran

<b>Cat. No.:</b>	HY-145720
<b>CAS No.:</b>	1639264-46-2
<b>Molecular Formula:</b>	C <sub>542</sub> H <sub>711</sub> F <sub>17</sub> N <sub>169</sub> O <sub>330</sub> P <sub>45</sub> S <sub>6</sub>
<b>Molecular Weight:</b>	16782.53
<b>Sequence:</b>	RNA, (Am-sp-Am-sp-(2'-deoxy-2'-fluoro)G-Cm-(2'-deoxy-2'-fluoro)A-Am-(2'-deoxy-2'-fluoro)G-Am-(2'-deoxy-2'-fluoro)U-(2'-deoxy-2'-fluoro)A-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)U-Um-Um-(2'-deoxy-2'-fluoro)A-Um-(2'-deoxy-2'-fluoro)A-Am-Um-Am), 3'-[[[(2S,4R)-1-[29-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-14,14-bis[[3-[[[5-[[2-(acetylamino)-2-deoxy-β-D-galactopyranosyl]oxy]-1-oxopentyl]amino]propyl]amino]-3-oxopropoxy]methyl]-1,12,19,25-tetraoxo-16-oxa-13,20,24-triazanonaco s-1-yl]-4-hydroxy-2-pyrrolidinyl]methyl hydrogen phosphate], complex with RNA (Um-sp-(2'-deoxy-2'-fluoro)A-sp-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)A-Um-Am-(2'-deoxy-2'-fluoro)A-Am-(2'-deoxy-2'-fluoro)A-Am-Um-Am-(2'-deoxy-2'-fluoro)U-Cm-(2'-deoxy-2'-fluoro)U-Um-(2'-deoxy-2'-fluoro)G-Cm-Um-Um-sp-Um-sp-Um-dTdT) (1:1)
<b>Target:</b>	Complement System; Small Interfering RNA (siRNA)
<b>Pathway:</b>	Immunology/Inflammation; Epigenetics
<b>Storage:</b>	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

# Cemdisiran

### SOLVENT & SOLUBILITY

#### In Vitro

H<sub>2</sub>O : ≥ 20 mg/mL (1.19 mM)  
\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
1 mM			0.0596 mL	0.2979 mL	0.5959 mL
5 mM			---	---	---
10 mM			---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

Cemdisiran is an N-acetylgalactosamine (GalNAc) conjugated siRNA for the research of complement-mediated diseases by suppressing liver production of complement 5 (C5) protein.

### REFERENCES

---

[1]. Badri P, Jiang X, Borodovsky A, et al. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365-378.

[2]. Prajakta Badri, et al. Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2021;60(3):365-378.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA